SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

TScan Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Announced strategic reorganization to focus on in vivo-engineered TCR-T cell therapy for solid tumor

TCRX

Related stories